(C3) (Lippman) - Moores Cancer Center

Report
San Diego NCI Cancer Centers Council (C3):
A Model for Multi‐Institutional Transdisciplinary Collaboration
Scott M. Lippman, MD
Director, Moores Cancer Center
2014 Cancer Center Administrators Forum
April 14, 2014
Evolution of the Moores Cancer Center
Strategic Recruits
Cancer Center Founded
John Mendelsohn, Director
Napoleone Ferrara
Basic Science
Moores Cancer Center
Opened
UCSD
SOM
Founded
Razelle Kurzrock
Clinical Science
Ezra Cohen
Translational
Science
‘14
NCI-designated
Cancer Center
Awarded
Comprehensive
Status
CCSG
Renewed
Dennis Carson
Director
CTSA
Awarded
Scott Lippman
Director
CCSG
Renewal
2
UCSD Moores Cancer Center
External Advisory Board
Senior Advisor to the Director
Thomas Kipps, MD, PhD
Deputy Director
Barbara Parker, MD
Administration
Ira Goodman, MPA, MS
Division of
Clinical Science
Razelle Kurzrock, MD
Research Programs
• Hematologic
Malignancies
• Solid Tumor
Therapeutics
Clinical Trials Office
Center Director
Associate Vice Chancellor
for Cancer Research and Care
Scott Lippman, MD
Executive Committee
Cancer Cabinet
Board of Visitors
Division of
Population Science
John Pierce, PhD
Research Programs
• Cancer Prevention
• Reducing Cancer
Disparities
Division of
Basic Science
Napoleone Ferrara, MD
Research Programs
• Cancer Biology
& Signaling
• Cancer Genomics
& Networks
Office of Industry Relations
Shared
Resources
Nicholas Webster, PhD
Shared Resources (7)
Biorepository & Tissue
Technology
Biostatistics
Genomics & Bioinformatics
Microscopy
Flow Cytometry
Transgenic/KO Mice
Diet & Physical Activity
3
FACILITIES
Moores
andtoOther
Cancer
Center
Facilities
Relation
Consortium
Partner
SDSU
Cancer Campus
on the UC San Diego Campus
Altman CTRI
SCRM
CALM
JMCHCC
CALM Center for Advanced
Laboratory Medicine
OP
JMC
Jacobs Medical Center
- Hospital for Cancer Care
MCC
CTRI
Clinical and Translational
Research Institute
OP
Outpatient Pavilion
CNT
Center for Novel
Therapeutics
CNT
LICR
MCC Moores Cancer Center
SCRM Sanford Consortium for
Regenerative Medicine
SIO
LICR
Ludwig Institute for
Cancer Research
SIO
Scripps Institution of
Oceanography
4
Catchment Area
REGIONAL IMPACT
San Diego
Imperial County
8th Largest city (1.33M)
• 5th Largest county (3.14M)
•
•
Population = 175K
• Poverty Rate = 23%
UCLA
USC
City of
Hope
UC Irvine
MCC
410 miles
AZ
Cancer
Center
5
Clinical Hub of Unique
Biomedical Environment
LIFE TECHNOLOGIES
(C3 MOU signed Oct 2012)
AMGEN
JANSSEN
Sanford Consortium for Regenerative Medicine
NOVARTIS
(opened Dec 2011; LIAI, Salk, S-B, MCC, TSRI)
THE SCRIPPS RESEARCH INSTITUTE
SCRM
SALK
PFIZER
SANFORD | BURNHAM
UCSD MOORES
LA JOLLA ALLERGY AND IMMUNOLOGY
JCVI
MERCK
San Diego State University
SDSU
(Formal consortium MOU signed Apr 2013)
16 miles
J. Craig Venter Institute - HLI
ILLUMINA
(opened Nov 2013; HLI MOU signed Feb 2014)
2nd largest life-sciences cluster in US
(Jones Lang LaSalle)
•
•
Advisory & Innovation Council
Center for Novel Therapeutics (CNT)
6
MCC / C3
Formal Affiliations / Timeline
HLI MOU signed
(Feb 2014)
Salk Gene Transfer Targeting
S-B High Throughput Screening
MCC Biorepository
C3 MOU signed
(Oct 12, 2012)
2012
Sanford Consortium for
Regenerative Medicine
(SCRM) opens (Dec 2011)
JCVI opened on UCSD
Campus (Nov 2013)
SDSU: Formal
consortium w/ MCC
MOU signed (Apr 2013)
2013
2014
Members from TSRI, LIAI
& JCVI join MCC faculty
C3 Pilot Grant RFA
(Feb 28, 2014)
C3 Retreat
(June 29, 2013)
SDSU: Federally-designated
Hispanic-serving Institute
(April 2012)
C3 Reception
at AACR
(Apr 7, 2014)
Pedal the Cause
Fundraiser
C3 Pilot Grant
Awards
(Oct 26, 2013)
(May 1, 2014)
Mahajani Symposium
(Sep 9, 2013)
C3 Steering Committee
Chair (rotating)
Members
Scott M. Lippman (UCSD Moores) *
Webster Cavenee (UCSD Moores)
David Cheresh (UCSD Moores)
Barbara Parker (UCSD Moores)
Co-Chairs
Tony Hunter (Salk)
Garth Powis (Sanford-Burnham)
Ron Evans
Inder Verma
Geoff Wahl
(Salk) *
(Salk)
(Salk)
Sara Courtneidge (Sanford-Burnham)
Ze’ev Ronai
(Sanford-Burnham)
Kristiina Vuori
(Sanford-Burnham) *
Ira Goodman
A.D. Admin
* All three Institutes are represented on the
AACR Board of Directors in 2014
(UCSD Moores)
C3 Resource Sharing
Participating SRs:
•
Negotiated an agreement to share unique resources at each institution that are
unavailable at the other 2 Cancer Centers (CC)
•
All institutions agreed to give CC members, no matter the institution, the same
priority and rates as internal CC users
•
Institutions agreed to reduce the IDC charged to users from the other 2 CC
Moores: from 45% to 16% (SOM Dean agreed to waive 29% academic portion)
Salk: from 95% to 16%
SBMRI: from 35% to 16%
•
CC agreed to cover IDC (16%) using developmental funds from their respective
CCSGs (not part of formal agreement)
•
All institutions agreed that standard services provided by the shared resources
would not involve intellectual property
•
C3 agreement has increased usage of the three cores by users at the other
CCs during the first year
CANCER CENTERS
COUNCIL
C3 Scientific Retreat:
June 29, 2013
Keynote Address
Tony Hunter, PhD
“Tyrosine Kinases in Cancer Biology
and Treatment: Past, Present, Future”
Sanford | Burnham Cancer Center
– High Throughput Screening Core
UC San Diego Moores Cancer Center
– Biorepository Core
Shared Resources Director
Craig Hauser, PhD
Core Leader
Michael Jackson, PhD
Core Users
Matthew Petroski, PhD
Jeffrey Smith, PhD
Robert Wechsler-Reya, PhD
Shared Resources Director
Nicholas Webster, PhD
Core Leader
Scott VandenBerg, MD, PhD
Core Users
Clark Chen, MD, PhD
Frank Furnari, PhD
Michael Karin, PhD
Andrew Lowy, MD
Salk Cancer Center
– Gene Transfer Targeting and Therapeutics Core
Shared Resources Director
James Fitzpatrick, PhD
Core Leader
Leszek Lisowski, PhD
Core Users
Jan Karlseder, PhD
Ben Spike, PhD
Support for C3 Team Science
C3 Website & Pilot Grant RFA
www.sdcancercouncil.org
C3 Pilot Grant Applications
PI
new
Title
Institutions
Ball/Kang
Predictive microenvironment for testing leukemia therapies
Moores/SBMRI
Castro/Burkhart
Targeting the Spliceosome in CLL
Moores/Moores
Chen/Snyder
Harnessing the anti-glioblastoma activity of extracellular vesicles (EV) derived from
human neural stem cells (hNSCs)
Moores/SBMRI
Durden/Snyder
Effects of dual PI-3K/Brd4 bromodomain inhibitors on NSCs and transformed NSCs
Moores/SBMRI
Field/Jackson
Small molecule screen for inhibitors of the GOLPH3 pathway
Moores/SBMRI
Harismendy/Wechsler-Reya
Mechanisms of resistance to HDAC inhibitors in medulloblastoma
Moores/SBMRI
Husain/Shaw
Oncogene addicted metabolic reprogramming of circulating tumor cells in lung
adenocarcinoma
Moores/Salk
Karin/Wahl
Applying p38 MAPK inhibitors to tackle breast cancer metastasis
Moores/Salk
Li/Zhou
Circulating microRNA in lung cancer early diagnosis
Lowy/Wahl
Stromal reprogramming to enhance the effectiveness of pancreatic cancer therapy
Moores/Salk
Madlensky/Wahl
Demonstrating the clinical utility of whole exome sequencing for cancer patients
Moores/Salk
Niwa/Heynan-Genel
Dissecting two distinct IRE1 RNase activities as a new therapeutic strategy in
multiple myeloma and other cancers
Moores/SBMRI
Puri/Schwab
Abl-mediated tyrosine-phosphorylation of p300 acetyl-transferase as a biomarker for
tumor chemo-resistance and dasatinib-sensitivity
Moores/SBMRI
Rana/Ramamoorthy
Identification of non-coding RNA targets in oncogenic KRAS driven colon cancer
SBMRI/Moores
Sicklick/Wechsler-Reya
Targeting imatinib-resistant, KIT-negative cells in human GISTs
Moores/SBMRI
Strongin/Bouvet
PTK7 pseudokinase, a novel marker and a drug target in metastatic cancer
SBMRI/Moores
Yu/Rana
APOBEC deaminases in primary and metastatic melanoma
Moores/SBMRI
Moores/SBMRI
San Diego NCI Cancer Centers Council (C3):
A Model for Multi‐Institutional Transdisciplinary Collaboration
Scott M. Lippman, MD
Director, Moores Cancer Center
Chugai Pharmaceutical Chair, Professor of Medicine
Associate Vice Chancellor for Cancer Research and Care

similar documents